What is the share price of Strides Pharma Science Ltd (STAR) today?
The share price of STAR as on 15th July 2025 is ₹906.20. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Strides Pharma Science Ltd (STAR) share?
The past returns of Strides Pharma Science Ltd (STAR) share are- Past 1 week: 3.98%
- Past 1 month: 2.13%
- Past 3 months: 46.30%
- Past 6 months: 47.07%
- Past 1 year: 127.92%
- Past 3 years: 508.94%
- Past 5 years: 390.79%
What are the peers or stocks similar to Strides Pharma Science Ltd (STAR)?
The peers or stocks similar to Strides Pharma Science Ltd (STAR) include:What is the dividend yield % of Strides Pharma Science Ltd (STAR) share?
The current dividend yield of Strides Pharma Science Ltd (STAR) is 0.44.What is the market cap of Strides Pharma Science Ltd (STAR) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Strides Pharma Science Ltd (STAR) is ₹8351.79 Cr as of 15th July 2025.What is the 52 week high and low of Strides Pharma Science Ltd (STAR) share?
The 52-week high of Strides Pharma Science Ltd (STAR) is ₹929.60 and the 52-week low is ₹394.17.What is the PE and PB ratio of Strides Pharma Science Ltd (STAR) stock?
The P/E (price-to-earnings) ratio of Strides Pharma Science Ltd (STAR) is 2.32. The P/B (price-to-book) ratio is 3.23.Which sector does Strides Pharma Science Ltd (STAR) belong to?
Strides Pharma Science Ltd (STAR) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Strides Pharma Science Ltd (STAR) shares?
You can directly buy Strides Pharma Science Ltd (STAR) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Strides Pharma Science Ltd
STAR Share Price
STAR Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
STAR Performance & Key Metrics
STAR Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
26.75 | 3.23 | 0.44% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
37.80 | 6.51 | 0.80% |
from 2 analysts
Price Upside
Earnings Growth
Rev. Growth
STAR Company Profile
Strides Pharma Science is a vertically integrated global pharmaceutical company engaged in the development and manufacturing of active pharmaceutical ingredients and formulations, as well as biotech
STAR Sentiment Analysis
STAR Sentiment Analysis
STAR Stock Summary · May 2025
The company has demonstrated remarkable financial resilience, achieving record profits and a 17.2% revenue growth, driven by strong operational efficiency and a strategic focus on product innovation. With a robust pipeline of over 150 Abbreviated New Drug Applications and significant potential in the controlled substance nasal spray segment, management is optimistic about future U.S. market expansion. Despite challenges in access markets and rising costs associated with new product filings, the commitment to maintaining a strong balance sheet and reducing gross debt underscores a proactive approach to financial health. The emphasis on R&D investments and automation enhances operational capacity, positioning the company favorably for sustained growth and improved EBITDA margins in the coming years.
STAR Stock Growth Drivers
STAR Stock Growth Drivers
7Strong Financial Performance
The company reported a robust financial performance for FY '25, achieving a revenue growth of
Operational Efficiency and Consistency
The company has demonstrated significant operational efficiency, achieving consistent quarter-on-quarter EBITDA growth over the past
STAR Stock Challenges
STAR Stock Challenges
4Debt Management Challenges
The company currently has a total debt of INR 1,800 crores and a net debt
Capital Expenditure Constraints
The company plans to reduce capital expenditures (capex) for FY '26 to lower levels than
STAR Forecast
STAR Forecasts
Price
Revenue
Earnings
STAR Share Price Forecast
STAR Share Price Forecast
All values in ₹
All values in ₹
STAR Company Revenue Forecast
STAR Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
STAR Stock EPS (Earnings Per Share) Forecast
STAR Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
STAR
STAR
Income
Balance Sheet
Cash Flow
STAR Income Statement
STAR Income Statement
Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 3,097.80 | 3,534.85 | 2,545.66 | 2,909.44 | 3,518.84 | 3,258.10 | 3,935.35 | 3,979.98 | 7,921.07 | 4,661.31 | ||||||||||
Raw Materials | 1,432.25 | 1,286.65 | 1,189.20 | 1,167.29 | 1,686.50 | 1,407.04 | 1,629.55 | 1,705.99 | 2,163.97 | 3,818.65 | ||||||||||
Power & Fuel Cost | 33.87 | 51.33 | 54.39 | 64.49 | 64.58 | 71.54 | 85.82 | 75.13 | 58.17 | |||||||||||
Employee Cost | 419.16 | 434.05 | 329.44 | 442.56 | 550.15 | 646.91 | 732.02 | 737.05 | 862.76 | |||||||||||
Selling & Administrative Expenses | 339.47 | 409.34 | 276.20 | 338.51 | 473.78 | 577.98 | 526.31 | 412.58 | 518.06 | |||||||||||
Operating & Other expenses | 54.45 | 313.14 | 196.74 | 525.25 | 98.10 | 797.39 | 724.88 | 620.57 | 201.96 | |||||||||||
EBITDA | 818.60 | 1,040.34 | 499.69 | 371.34 | 645.73 | -242.76 | 236.77 | 428.66 | 4,116.15 | 842.66 | ||||||||||
Depreciation/Amortization | 126.15 | 154.04 | 117.39 | 173.70 | 206.29 | 233.01 | 243.25 | 213.64 | 192.26 | 194.32 | ||||||||||
PBIT | 692.45 | 886.30 | 382.30 | 197.64 | 439.44 | -475.77 | -6.48 | 215.02 | 3,923.89 | 648.34 | ||||||||||
Interest & Other Items | 183.10 | 196.24 | 79.29 | 155.72 | 150.07 | 176.74 | 261.14 | 280.22 | 248.85 | 256.71 | ||||||||||
PBT | 509.35 | 690.06 | 303.01 | 41.92 | 289.37 | -652.51 | -267.62 | -65.20 | 3,675.04 | 391.63 | ||||||||||
Taxes & Other Items | 109.60 | 25.55 | -21.60 | 5.53 | 20.94 | -192.30 | -65.00 | 5.41 | 81.58 | 79.41 | ||||||||||
Net Income | 399.75 | 664.51 | 324.61 | 36.39 | 268.43 | -460.21 | -202.62 | -70.61 | 3,593.46 | 312.22 | ||||||||||
EPS | 18.97 | 31.50 | 15.63 | 1.78 | 13.12 | -22.47 | -9.86 | -3.40 | 238.07 | 33.88 | ||||||||||
DPS | 1.91 | 0.85 | 1.31 | 6.13 | 1.10 | 0.00 | 0.66 | 1.10 | 4.00 | 1.09 | ||||||||||
Payout ratio | 0.10 | 0.03 | 0.08 | 3.45 | 0.08 | 0.00 | — | — | 0.02 | 0.03 |
STAR Company Updates
Investor Presentation
STAR Stock Peers
STAR Past Performance & Peer Comparison
STAR Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Strides Pharma Science Ltd | 2.32 | 3.23 | 0.44% |
Sun Pharmaceutical Industries Ltd | 37.93 | 5.72 | 0.93% |
Cipla Ltd | 22.84 | 3.85 | 1.07% |
Torrent Pharmaceuticals Ltd | 60.91 | 15.34 | 0.93% |
STAR Stock Price Comparison
Compare STAR with any stock or ETFSTAR Holdings
STAR Shareholdings
STAR Promoter Holdings Trend
STAR Promoter Holdings Trend
In last 6 months, promoter holding in the company has increased by 2.46%
A significant proportion of promoter holdings is pledged
STAR Institutional Holdings Trend
STAR Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
STAR Shareholding Pattern
STAR Shareholding Pattern
STAR Shareholding History
STAR Shareholding History
Mutual Funds Invested in STAR
Mutual Funds Invested in STAR
No mutual funds holding trends are available
Top 5 Mutual Funds holding Strides Pharma Science Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 3.5838% | Percentage of the fund’s portfolio invested in the stock 1.01% | Change in the portfolio weight of the stock over the last 3 months 0.12% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 25/119 (+2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.5254% | Percentage of the fund’s portfolio invested in the stock 1.26% | Change in the portfolio weight of the stock over the last 3 months 0.25% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 51/86 (-32) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9580% | Percentage of the fund’s portfolio invested in the stock 0.62% | Change in the portfolio weight of the stock over the last 3 months 0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 163/210 (0) |
Compare 3-month MF holding change on Screener
smallcases containing STAR stock
smallcases containing STAR stock
Looks like this stock is not in any smallcase yet.
STAR Events
STAR Events
STAR Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
STAR Dividend Trend
No dividend trend available
STAR Upcoming Dividends
STAR Upcoming Dividends
Cash Dividend
Ex DateEx DateJul 22, 2025
Dividend/Share
₹4.00
Ex DateEx Date
Jul 22, 2025
STAR Past Dividends
STAR Past Dividends
Cash Dividend
Ex DateEx DateSep 9, 2024
Dividend/Share
₹2.50
Ex DateEx Date
Sep 9, 2024
Cash Dividend
Ex DateEx DateAug 4, 2023
Dividend/Share
₹1.50
Ex DateEx Date
Aug 4, 2023
Cash Dividend
Ex DateEx DateAug 5, 2021
Dividend/Share
₹2.50
Ex DateEx Date
Aug 5, 2021
Cash Dividend
Ex DateEx DateJul 24, 2020
Dividend/Share
₹2.00
Ex DateEx Date
Jul 24, 2020
Cash Dividend
Ex DateEx DateAug 22, 2019
Dividend/Share
₹12.00
Ex DateEx Date
Aug 22, 2019
STAR Stock News & Opinions
STAR Stock News & Opinions
Strides Pharma Science announced that the 34th Annual General Meeting(AGM) of the company will be held on 7 August 2025.Powered by Capital Market - Live
Strides Pharma Science has fixed 22 July 2025 as record date for final dividend of Rs 4 per share of face value of Rs 10 each for FY 2025. Powered by Capital Market - Live
Strides Pharma Science announced that the Board of Directors of the Company at its meeting held on 22 May 2025, inter alia, have recommended the final dividend of Rs 4 per equity Share (i.e. 40%) , subject to the approval of the shareholders.Powered by Capital Market - Live
Net profit of Strides Pharma Science rose 352.09% to Rs 82.19 crore in the quarter ended March 2025 as against Rs 18.18 crore during the previous quarter ended March 2024. Sales rose 14.08% to Rs 1190.39 crore in the quarter ended March 2025 as against Rs 1043.50 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 3593.46 crore in the year ended March 2025 as against net loss of Rs 70.62 crore during the previous year ended March 2024. Sales rose 17.36% to Rs 4565.34 crore in the year ended March 2025 as against Rs 3890.13 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales1190.391043.50 14 4565.343890.13 17 OPM %18.3016.23 -17.5813.58 - PBDT182.6684.69 116 614.52287.89 113 PBT133.8036.76 264 422.2674.25 469 NP82.1918.18 352 3593.46-70.62 LP Powered by Capital Market - Live
Strides Pharma Science will hold a meeting of the Board of Directors of the Company on 22 May 2025.Powered by Capital Market - Live
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs (Urinary Tract Infections), Pain Management, Allergy Symptoms and Attention Deficit Disorder (ADD/ ADHD) and Narcolepsy. Two (out of the four) ANDAs acquired are commercial products and is expected to be launched within 12 months. With access to these products, Strides will expand its portfolio of niche and difficult to manufacture products. The cumulative market size for the acquired portfolio is around $57 million as per IQVIA data of 2025. Total consideration for acquisition of the said ANDAs is $ 2.075 million (Rs 17.6 crore). Strides Pharma Science is global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures wide range of niche and technically complex pharmaceutical products The company's consolidated net profit jumped 77.1% to Rs 87.95 crore on 14.7% increase in net sales to Rs 1153.67 crore in Q3 FY25 over Q3 FY24. The counter declined 1.61% to end at Rs 652.55 on Tuesday, 29 April 2025.Powered by Capital Market - Live
Arco Lab, a wholly owned subsidiary of Strides Pharma Science has incorporated a new wholly owned subsidiary viz., 'Pivot Path' on 10 April 2025. Powered by Capital Market - Live
Strides Pharma Global (SPG), a step-down wholly-owned subsidiary of Strides Pharma Science in Singapore, proposes to create a platform that shall foster introductions, collaborations, procurement and business engagement between pharmaceutical manufacturers and suppliers of India, China, and other Southeast-Asian countries. In this regard, it is proposed to acquire 100% stake in Amexel, Singapore, which will be utilized as the entity for the above business platform. SPG has entered into a Share Purchase Agreement to acquire 100% stake in Amexel for a nominal consideration of USD 10. Amexel, as WOS of SPG, shall focus on: 'h - in-licensing, technology transfers, and the procurement of technical and manufacturing expertise for the production of pharmaceutical products at Strides'' manufacturing facilities (or those of its affiliates) as well as other manufacturers in India. 'h - identifying qualified and approved suppliers, sourcing partners, and providers of APIs, Raw Materials and Packaging materials. 'h - building partnerships with distributors, commercial partners, and customers to support the supply, distribution, and commercialization of products across various territories. Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products. Powered by Capital Market - Live
Strides Pharma Science announced the change in designation of Arun Kumar (DIN: 00084845) from Executive Chairperson to Non-Executive Chairperson of the Company effective 05 April 2025. Arun Kumar, Founder and Executive Chairperson of the Company, has served in various positions on the Board of Strides since its inception. His current appointment as Executive Director is expiring on 06 April 2025. Upon successful transition of executive responsibilities to Badree Komandur (who was appointed as Managing Director and Group CEO effective 01 June 2024) and the Leadership team at Strides, Arun has opted to assume the role of Non-Executive Chairperson effective 05 April 2025.Powered by Capital Market - Live
Strides Pharma Science has appointed Mukta Arora (DIN: 07225715) as Independent Director of the Company effective 01 February 2025. Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 22.18%, vs industry avg of 10.15%
Over the last 5 years, market share increased from 1.16% to 1.9%
Over the last 5 years, net income has grown at a yearly rate of 150.56%, vs industry avg of 20.04%